Literature DB >> 36018490

Conundrum of Clinical QTc Monitoring.

Marek Malik1,2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 36018490     DOI： 10.1007/s40264-022-01229-5

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.228


× No keyword cloud information.
  28 in total

1.  A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model.

Authors:  Eline Vandael; Bert Vandenberk; Joris Vandenberghe; Bart Van den Bosch; Rik Willems; Veerle Foulon
Journal:  Br J Clin Pharmacol       Date:  2018-10-06       Impact factor: 4.335

2.  Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.

Authors:  Rossanna C Pezo; Andrew T Yan; Craig Earle; Kelvin K Chan
Journal:  Heart       Date:  2019-05-25       Impact factor: 5.994

3.  Providers' Response to Clinical Decision Support for QT Prolonging Drugs.

Authors:  Sunita Sharma; J Martijn Bos; Robert F Tarrell; Gyorgy J Simon; Bruce W Morlan; Michael J Ackerman; Pedro J Caraballo
Journal:  J Med Syst       Date:  2017-09-02       Impact factor: 4.460

4.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

Review 5.  Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

Authors:  Peter J Schwartz; Raymond L Woosley
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

Review 6.  Risk factors for QTc-prolongation: systematic review of the evidence.

Authors:  Eline Vandael; Bert Vandenberk; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2016-12-23

7.  Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol.

Authors:  Miriam Jacoba Warnier; Frans Hendrik Rutten; Patrick Cyriel Souverein; Anthonius de Boer; Arno Wilhelmus Hoes; Marie Louise De Bruin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-05-27       Impact factor: 2.890

Review 8.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

9.  Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.

Authors:  James E Tisdale; Heather A Jaynes; Joanna R Kingery; Noha A Mourad; Tate N Trujillo; Brian R Overholser; Richard J Kovacs
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-05-28

10.  Assessing Prescriber Behavior with a Clinical Decision Support Tool to Prevent Drug-Induced Long QT Syndrome.

Authors:  Katy E Trinkley; Jonathan M Pell; Dario D Martinez; Nicola R Maude; Gary Hale; Michael A Rosenberg
Journal:  Appl Clin Inform       Date:  2021-03-10       Impact factor: 2.342
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.